Straits Times Index
3,292.93 -3.96 (-0.12%) S&P 500
5,127.79 +63.59 (+1.26%) Dow
38,675.68 +449.98 (+1.18%) Nasdaq
16,156.33 +315.33 (+1.99%) Bitcoin USD
64,106.33 +590.43 (+0.93%) CMC Crypto 200
1,335.28 +58.30 (+4.57%)
INVA May 2024 12.500 call
| Previous close | 2.9800 |
| Open | 2.9800 |
| Bid | 2.2500 |
| Ask | 4.6000 |
| Strike | 12.50 |
| Expiry date | 2024-05-17 |
| Day's range | 2.9800 - 2.9800 |
| Contract range | N/A |
| Volume | |
| Open interest | 18 |
Business WireInnoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
WALTHAM, Mass., April 24, 2024--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), today announced that positive results from the Phase 3 oral zoliflodacin trial will be highlighted in an oral presentation given by the Global Antibiotic Research & Development Partnership (GARDP) at the European Society of Clinical Microbiology and Infectious Disease Global Congress (ESCMID Global 2024) taking place April 27-30, 2024, in Barcelona, Spain. Zoliflodacin is a first
Simply Wall St.Should Weakness in Innoviva, Inc.'s (NASDAQ:INVA) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
It is hard to get excited after looking at Innoviva's (NASDAQ:INVA) recent performance, when its stock has declined 10...
PR NewswireArmata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has entered into a secured credit agreement with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, "Innoviva"), Armata's largest shareholder. The gross proceeds to be received by the C
